TFA Therapeutics RAJAF
OTC RAJAF
$9.18 +0.00 (+0.00%)
At close: Sep 29, 2026 · 4:00 PM EDT

TFA Therapeutics (RAJAF) EBITDA Margin (2023)

Updated

TFA Therapeutics' EBITDA Margin was 5.47% in FY2025, down 13.69 percentage points from 19.16% in FY2024.

Analysis

TFA Therapeutics (RAJAF) EBITDA Margin (2023) Analysis & Trends

From FY2020 onward, TFA Therapeutics has reported EBITDA Margin for 6 years.

  • EBITDA Margin shows a five-year change of -20.78 percentage points (FY2020 to FY2025).
  • The FY2025 figure marks the lowest annual EBITDA Margin since FY2022.
  • Per Business Quant data, EBITDA Margin in earlier years was 19.16% in FY2024 (-22.86 pp), 42.02% in FY2023 (+668.55 pp), -626.53% in FY2022 (-630.48 pp) and 3.96% in FY2021 (-22.30 pp).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Procter & Gamble 337.81 Bn 293.80 Bn 10.28 Bn 22.46%
2 Colgate Palmolive 68.01 Bn 63.06 Bn 3.30 Bn 21.84%
3 Kenvue 33.93 Bn 29.54 Bn 2.30 Bn 21.34%
4 Estee Lauder Companies 33.63 Bn 21.70 Bn 2.74 Bn 4.38%
5 Kimberly Clark 32.41 Bn 29.73 Bn 1.60 Bn 19.10%
6 Church & Dwight 22.35 Bn 20.88 Bn 693.90 Mn 25.03%
7 Clorox 9.80 Bn 8.24 Bn 804.00 Mn 28.34%
8 e.l.f. Beauty 5.95 Bn 4.92 Bn 398.84 Mn 26.81%
9 Reynolds Consumer Products 4.56 Bn 4.22 Bn 245.00 Mn 18.01%
10 TFA Therapeutics 1.02 Bn 1.02 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 93.34%
API Access

TFA Therapeutics EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=RAJAF&period=max&api_key=YOUR_API_KEY